B cell lymphomaLYMPHOMASTISSUE woundsWOUNDS & injuriesMEDICAL recordsBACKGROUND: Primary cutaneous marginal zone B-cell lymphoma (PCMZL) has rarely been reported in patients younger than 20 years. OBJECTIVES: To report our experience with PCMZL in the paediatric/adolescent age group. METHODS: Medical...
Nathwanni BN, Ullrich F, Weisenburger DD, for the non-Hodgkin’s lymphoma classification project (2002) Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the up-dated Kiel classification. Leukemia Lymphoma 43: 97–104 ...
但对于FDG亲和性差的淋巴瘤亚型(如惰性淋巴瘤),治疗前的分期检查仍以增强CT扫描为首选。 ② 如果有影像学的临床指征,PET-CT可用于治疗中期疗效评价,但仍处于临床研究阶段,故根据中期PET-CT结果更改治疗方案仍须慎重。 ③ 对于HL和多数弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL),如果PET-CT提示...
但对于FDG亲和性差的淋巴瘤亚型(如惰性淋巴瘤),治疗前的分期检查仍以增强CT扫描为首选。 ② 如果有影像学的临床指征,PET-CT可用于治疗中期疗效评价,但仍处于临床研究阶段,故根据中期PET-CT结果更改治疗方案仍须慎重。 ③ 对于HL和多数弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL),如果PET-CT提示...
Zhen Wang3, Li Wang1, Lei Fan1, Dong Hua2,Yao-Yu Chen1, Wei Xu1, Zhi-Hong Zhang3 & Jian-Yong Li1,4 Using an immunohistochemistry (IHC) based method, diffuse large B-cell lymphoma (DLBCL) can be classified into germinal center B-cell (GCB) and non-GCB subtypes...
参考文献:Junmin Wang et al, A New Staging System Based on the Dynamic Prognostic Nomogram for Elderly Patients With Primary Gastrointestinal Diffuse Large B-Cell Lymphoma, Frontiers in Medicine (2022). DOI 10.3389fmed.2022.8...
[2]. Kuper-Hommel MJJ, Janssen-Heijnen MLG, Vreugdenhil G et al. Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. Leuk Lymphoma 2012; 53: 242–246. [3]. Kraan W, Horli...
The international staging system (ISS), based on serum beta-2 microglobulin and albumin, is used to predict survival in multiple myeloma, but its prognostic significance in diffuse large B-cell lymphoma (DLBCL) remains unknown. Herein, we retrospectively analyzed 215 de novo DLBCL patients. Accordi...
Regulatory T cells (Tregs) induce immune responses and may contribute to immune escape in tumors. Accumulation of Tregs in tumors represents a critical barrier to anti-tumor immunity and immunotherapy. However, conflicting results describing the role of
In contrast to many other B-cell lymphoma entities, there are no genetic aberrations that are common to all CLL patients. Several recurrent aberrations have been characterized, where the most frequent are deletion of 13q14 (50–55%), deletion of 11q22-23 (12–18%),trisomy 12(11–16%) ...